Kontakt

Sanofi AB
Lindhagensgatan 120 
Box 30052
104 25 Stockholm 
Sverige

Telefon: 08-634 50 00
Kontakta oss

Apidra - snabbhet, när det behövs!

Dokumentation för Apidra

Endast för vårdpersonal!

  • Skriv ut
  • Larger Smaller

    Teckenstorlek

  • Uppdaterad : 2016-02-26

Nedan finns en sammanställning av dokumentation för Apidra®.

Studier på typ 1-diabetes

Dreyer et al. Efficacy and Safety of Insulin Glulisine in Patients With Type 1 Diabetes, Hormon Metab Res 2005;37:702-707

Garg et al. Optimized Basal-Bolus Insulin Regimens in Type 1 Diabetes: Insulin Glulisine Versus Regular Human Insulin in Combination With Basal Insulin Glargine, Endocr Practice 2005:11;11-17

Hoogma et al. Safety of Insulin Glulisine when Given by Continuous Subcutaneous Infusion Using an External Pump in Patients with Type 1 Diabetes Horm Metab Res 2006; 38: 429±433         

Danne et al. Pharmacokinetics, Prandial Glucose Control, and Safety of Insulin Glulisine in Children and Adolescents With Type 1 Diabetes. Diabetes Care, Vol 28, No 9, September 2005

Studier på typ 2-diabetes

Dailey et al. InsulinGlulisine Provides Improved Glycemic Control in Patients With Type 2-Diabetes, Diabetes Care 2004;27:2363-2368

Farmakokinetik

Becker R et al. Insulin Glulisine, a New Rapid Acting Insulin Analogue, Displays A Rapid Time-Action Profile in Obese Non-Diabetic Subjects, Exp Clin Endocrinol Diabetes 2005;113:435–443

Heise et al. Insulin glulisine: a faster onset of action compared with insulin lispro, Diabetes, Obesity and Metabolism, 9, 2007, 746–753

In vivo studier

Henninge et al. Insulin Receptor Signaling Characteristics In Vivo, Diabetes 2005:54;361-366

Rakatzi et al. A Novel Insulin Analog With Unique Properties, Diabetes 2003:52;2227-2238

Rakatzi et al. [LysB3, GluB29] insulin: a novel insulin analog with enhanced–cell protective action, Biochemical and Biophysical Research Communications 2003:310;852-859